ICER is a nonprofit that regularly analyses the cost-effectiveness of prescription drugs.
Remdesivir involves a 10-day treatment regimen, and ICER said a fair cost for the course of treatment would be $4,460, based on quality of life years gained and assuming the value of each year is $50,000.
Gilead hasn’t said how much it will charge for the drug, but has donated its entire supply — about 1.5 million vials — to the U.S. government.
Gilead CEO Daniel O’Day also wrote an open letter in March promising the company would work to ensure affordability and access to remdesivir.
The drugmaker said it’s aiming to make a million doses of the drug by the end of the year.
More articles on pharmacy:
6 federal pharmacy policy changes in response to the COVID-19 pandemic
Clinical trials for COVID-19 drugs & when to expect results
Walgreens lowers prices on hundreds of prescription drugs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.